Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe Cooper Health System

About this trial

The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are:

Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life?

Participants will:

Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake.

Continue using the spirometer daily during treatment and for up to three months after treatment.

Complete quality of life assessments at the start of the study and at 3, 6, and 12 months.

Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.

Eligibility criteria

Qualifiers

Confirmed diagnosis of advanced non-small-cell lung cancer

Performance status (ECOG 0-1)

Eligible for concurrent chemotherapy and radiation

18 years or older

Disqualifiers

Previous lung or thoracic surgery

Enrollment in another pulmonary intervention trial

Home oxygen usage prior to enrolment

Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging

Trial design

Treatments tested in this trial

  • incentive spirometry

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators

The Cooper Health System

Lead sponsor

The Cooper Foundation

Collaborator